News
11-25-2013, 05:21 AM
Celgene International SÃ*rl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
More... (http://www.news-medical.net/news/20131125/CHMP-adopts-positive-opinion-for-ABRAXANE-with-gemcitabine-for-treatment-of-metastatic-pancreas.aspx)
More... (http://www.news-medical.net/news/20131125/CHMP-adopts-positive-opinion-for-ABRAXANE-with-gemcitabine-for-treatment-of-metastatic-pancreas.aspx)